Pub. Date : 2010 May 4
PMID : 20337484
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | c-Abl and b-Raf are major targets of marketed oncology drugs Imatinib (Gleevec) and Sorafenib (Nexavar), respectively, and BIRB-796 is a p38alpha inhibitor that reached Phase II clinical trials. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
2 | c-Abl and b-Raf are major targets of marketed oncology drugs Imatinib (Gleevec) and Sorafenib (Nexavar), respectively, and BIRB-796 is a p38alpha inhibitor that reached Phase II clinical trials. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |